Navigation Links
Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD
Date:10/30/2009

us needs of patients diagnosed with ADHD. Once-daily Daytrana is a transdermal alternative to oral immediate- and extended-release formulations of methylphenidate, an active ingredient that has been used to treat ADHD for over 50 years," said Michael Yasick, Senior Vice President of the ADHD Business Unit at Shire. "The short term efficacy and safety profile of Daytrana in adolescents has been previously reported and this Shire-supported study examined the tolerability and effectiveness of the medication in the adolescent population over an extended period of six months."

Long-Term Open-Label Tolerability and Effectiveness Study in Adolescents with ADHD

In this study, Daytrana participants were titrated to their optimal dose over five weeks and were then maintained on that dose for an additional five months. Participants from a previous double-blind, seven week study were able to enroll. In this seven week study, Daytrana was shown to significantly improve ADHD symptoms as rated by clinicians and parents compared with placebo. The frequency of adverse events was typical of these seen in studies of oral methylphenidate in adolescents, with the exception of dermal reactions. The long term extension study evaluated four doses of the Daytrana patch worn for nine hours at alternating hips and used for about six months. Most adverse events were mild to moderate in intensity. The most commonly reported treatment-emergent adverse events reported by 5 percent or more of participants that received Daytrana were decreased appetite (11.0 percent); headache (10.1 percent); upper respiratory tract infection (10.1 percent); nasopharyngitis (inflammation of the nasal passages and of the upper part of the pharynx) (9.2 percent); and irritability (5.5 percent). The majority (93.6 percent) of skin response scores were defined as no irritation or minimal to definite redness.

The primary effect
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Shire Continues to Deliver Excellent Growth From Core Products
2. Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30
3. Shire Presents Results of Five Lialda(R) (mesalamine) Analyses at ACG 2009 Annual Scientific Meeting
4. Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA
5. Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R)
6. Veriscrip and DAMMAD Team Up to Combat Prescription Drug Abuse in New Hampshire
7. New Hampshire Rx Card Launching Statewide
8. Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
9. Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials
10. Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... SILVER SPRING, Md. , Aug. 29, 2014 /PRNewswire/ ... today that the U.S. District Court for the District ... in its favor in the company,s case against Sandoz, ... opinion, Judge Peter Sheridan ruled that U.S. ... Sandoz, Inc., and enjoined Sandoz from marketing its generic ...
(Date:8/29/2014)... DALLAS , August 29, 2014 ... Synthesis Market by Product & Services (Equipment, Reagent, ... Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, ... by MarketsandMarkets, the global Oligonucleotide Synthesis Market is ... $1,070.7 Million in 2014, growing at a CAGR ...
(Date:8/29/2014)... Aug. 29, 2014  Unilife Corporation ("Unilife" or "Company") ... that it intends to release its financial results for ... 30, 2014 after market trading ends on Tuesday, September ... conference call for 4:30 p.m. U.S. EDT on Tuesday, ... a.m. AEST), to review the Company,s financial results, commercial partnerships, ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... September 15 NicOx S.A. (Euronext,Paris: COX) today ... study for naproxcinod in 1020 patients with osteoarthritis ... naproxcinod (750 mg and 375 mg bid) met,the ... study,also comfortably met the main secondary endpoint, demonstrating ...
... ... Osteoarthritis, WALTHAM, ... announced today that Kenneth Kornman, Ph.D.,the company,s Chief Scientific Officer, ... (OA) at the 2008 World Congress,on Osteoarthritis, sponsored by the ...
Cached Medicine Technology:NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect 2NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect 3NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect 4NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect 5Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis 2Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis 3Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis 4
(Date:8/30/2014)... Colorado (PRWEB) August 30, 2014 Daily Gossip ... called the Make Him Desire You program, who shows a ... , The author of this method says that the program ... , The Make Him Desire You review indicates that the ... amazing insider advice and his great techniques to make a ...
(Date:8/30/2014)... 2014 Daily Gossip reveals in its recently ... a method created by Sarah Summer, who can perfectly understand ... of this new program actually had to deal with this ... be able to access it, in an all-natural holistic cure ... finding an effective cure for yeast infection. The author of ...
(Date:8/30/2014)... New York (PRWEB) August 30, 2014 ... combination of Nutrition and Pharameuticals. Nutraceuticals is a ... extracting healthy ingredients from natural food sources. Nutraceutical ... health benefits to the human body. Nutraceutical health ... diet supplements, fortified foods and more. Although nature ...
(Date:8/30/2014)... August 30, 2014 Ticket Down ... Open Tennis Championship tickets in NYC. This ... code US-OPEN-2014 for all day session, evening session, courtside ... sales for this prestigious Grand Slam Tournament. , The ... 8/30/14 , US Open Tennis Championship: Men's/Women's 3rd Round ...
(Date:8/30/2014)... After offering hyperbaric oxygen therapy ... past several years, Dr. Roy Schmidt and the ... a scholarship program for veterans who have been ... held this summer to discuss veterans’ needs ( ... shed light on the large number of veterans ...
Breaking Medicine News(10 mins):Health News:Make Him Desire You Review Reveals Powerful Formula to Make a Man Emotionally Addicted 2Health News:Natural Cure for Yeast Infection Review Exposes New Natural Treatment 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 3Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 3Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 5Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2
... Ophthalmology hosts event October 24 benefiting,Juvenile Diabetes Research ... Oct. 17 Oklahoma Academy of,Ophthalmology (OAO) hosts ... Research Foundation (JDRF) Central Oklahoma Chapter., Actor, ... the,event. Lorena and Gary Story of Oklahoma City ...
... (Caltech) have created a "plug-and-play" synthetic RNA device--a sort ... in and responding to more than one biological or ... such devices could have a multitude of potential medical ... tumor cells or determine when to turn modified genes ...
... Behind New Resource, KUMASI, Ghana, Oct. 17 ... new hopeXchange Medical Center, a high quality,diagnostic and ... the ceremony, President Kufuor welcomed a high-profile mission,delegation ... the Cure(R),s President,and CEO Hala Moddelmog, and acknowledged ...
... MINNETONKA, Minn., Oct. 17 Cancer and its ... amounts of calories,protein and nutrients they need to help ... lose significant amounts of lean,muscle mass and weight because ... strong aversion to foods. These symptoms can lead to ...
... Mich., Oct. 17 Chrysler LLC and Henry,Ford ... bring an,innovative diabetes program to its Sterling Stamping ... the Henry Ford Health System,and is intended to ... existing workplace wellness initiatives. All employees at the,site ...
... Satyam Computer,Services Ltd. (NYSE: SAY ), a ... reported US GAAP results for its second,quarter, which ... Despite a challenging market that impacted several key ... exceeded its guidance in,the second quarter. Revenue was ...
Cached Medicine News:Health News:Second Annual 'Eye Ball' Fights Juvenile Diabetes, Says Oklahoma Academy of Ophthalmology 2Health News:Second Annual 'Eye Ball' Fights Juvenile Diabetes, Says Oklahoma Academy of Ophthalmology 3Health News:Caltech engineers build first-ever multi-input 'plug-and-play' synthetic RNA device 2Health News:New Specialty Hospital Dedicated in Ghana is Key Component of Susan G. Komen for the Cure(R)'s Debut in Africa 2Health News:New Specialty Hospital Dedicated in Ghana is Key Component of Susan G. Komen for the Cure(R)'s Debut in Africa 3Health News:New Specialty Hospital Dedicated in Ghana is Key Component of Susan G. Komen for the Cure(R)'s Debut in Africa 4Health News:Strong Bodies Battle Better 2Health News:Strong Bodies Battle Better 3Health News:Chrysler LLC Launches Workplace Diabetes Education Program 2Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 2Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 3Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 4Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 5Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 6Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 7Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 8Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 9Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 10
... to having been designed exclusively for vascular treatments, ... the Smartepil range which ensures fast amortisation of ... systems, it can be fitted with a polarised ... the target to be treated as well as ...
... SmartLite Derm is a KTP laser, ... of 532 nm (frequency doubled Nd:YAG) for ... by the comfortable color LCD Touch-screen. ... available are 0.3, 0.5, 0.7 and 1.0 ...
... a new and powerful instrument for ... system (MEL @308 nm - UVB) ... vitiligo. Designed to treat recalcitrant plaques, ... exposure of extensive lesions without irradiating ...
... a CO2 laser system with CW intensities ... dealing with all therapeutic application in modern ... medium-to-high intensities in super-pulsed mode, designed for ... It is also capable of supplying soft ...
Medicine Products: